News | October 20, 2022
Lupin to acquire two inhalation brands from Sunovion for US$75 million
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Government Ayurveda College & Hospital will include an infrastructure for the College and a 100 bedded hospital, hostel block for students and staff quarters.
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
The company increases its efficiency and is able to face the growing demand for its services.
Subscribe To Our Newsletter & Stay Updated
